Thursday, June 8, 2017

SciClone Acquired For $605M Chinese Investors

Foster City-based SciClone Pharmaceuticals, a developer of pharmaceuticals aimed at treating oncology, infectious diseases and cardiovascular disorders, said today that it has reached a deal to be acquired by a Chinese investment consortium, in a deal worth approximately $605M in cash. The publicly traded company, which trades as SCLN on the NASDAQ, said that the consortium is led by GL Capital, and also included Bank of China Group Investment Limited, CDH Investments, Ascendent Capital Partners and Boying. The deal translates to $11.18 per share in cash.